Vertex Pharmaceuticals Inc (VRTX) Stock Analysis — PE Ratio, PS Ratio, Intrinsic Value & 2030 Price Target
Vertex Pharmaceuticals Inc stock (VRTX) is currently trading at $454.00. Vertex Pharmaceuticals Inc PE ratio is 30.40. Vertex Pharmaceuticals Inc PS ratio (Price-to-Sales) is 9.86. Analyst consensus price target for VRTX is $545.50. WallStSmart rates VRTX as Moderate Buy.
Vertex Pharmaceuticals Inc (VRTX) stock price prediction for 2030: Base case $389.60. Bull case $487.00. Bear case $292.20. See full VRTX 2030 price forecast and methodology on WallStSmart.
- VRTX PE ratio analysis and historical PE chart
- VRTX PS ratio (Price-to-Sales) history and trend
- VRTX intrinsic value — DCF, Graham Number, EPV models
- VRTX stock price prediction 2025 2026 2027 2028 2029 2030
- VRTX fair value vs current price
- VRTX insider transactions and insider buying
- Is VRTX undervalued or overvalued?
- Vertex Pharmaceuticals Inc financial analysis — revenue, earnings, cash flow
- VRTX Piotroski F-Score and Altman Z-Score
- VRTX analyst price target and Smart Rating
Vertex Pharmaceuticals Inc
📊 No data available
Try selecting a different time range
VRTX Intrinsic Value Analysis for Value Investors
Benjamin Graham Formula · Vertex Pharmaceuticals Inc (VRTX)
VRTX trades at a significant discount to its Graham intrinsic value of $717.44, offering a 37% margin of safety — a level value investors typically seek before buying.
Based on Benjamin Graham Formula. Growth rate capped at 25%. For informational purposes only. Not financial advice.
Smart Analysis
Vertex Pharmaceuticals Inc (VRTX) · 10 metrics scored
Smart Score
Category Performance
WallStSmart pulls financial metrics like revenue growth, profit margins, and valuation ratios and scores each one from 0 to 10 based on how strong or weak it is. Those 10 scores are grouped into 4 categories: Growth, Profitability, Valuation, and Quality — which form the 4 axes of the spider chart you see. The categories are then combined into a final score out of 100, but not equally. Growth and Profitability together count for 60% of the total, because a fast-growing profitable business matters more than just a cheap one. That final number maps to a rating (Strong Buy, Buy, Hold, Avoid) and a letter grade, giving you one clear Stock Rating.
Investment Thesis
Strong fundamentals in market cap, return on equity, operating margin. Concerns around price/sales and price/book. Overall metrics suggest strong investment potential with favorable risk/reward.
Vertex Pharmaceuticals Inc (VRTX) Key Strengths (6)
Keeps $40 of every $100 in revenue after operating costs
Earnings per share surging 32.90% year-over-year
Keeps $33 of every $100 in revenue as net profit
97.67% of shares held by major funds and institutions
Large-cap company with substantial market presence
Every $100 of equity generates $23 in profit
Supporting Valuation Data
Vertex Pharmaceuticals Inc (VRTX) Areas to Watch (4)
Very expensive at 9.9x annual revenue
Very expensive at 6.4x book value
Paying a premium for growth, expensive relative to earnings expansion
Modest revenue growth at 9.50%
Supporting Valuation Data
Vertex Pharmaceuticals Inc (VRTX) Detailed Analysis Report
Overall Assessment
This company scores 66/100 in our Smart Analysis, earning a B- grade. Out of 10 metrics analyzed, 6 register as strengths (avg 9.7/10) while 4 fall into concern territory (avg 3.0/10). The category breakdown reveals uneven performance, with some areas requiring attention.
The Bull Case
The strongest argument centers on Operating Margin, EPS Growth, Profit Margin. Profitability is solid with Return on Equity at 22.50%, Operating Margin at 39.60%, Profit Margin at 32.90%. Growth metrics are encouraging with EPS Growth at 32.90%.
The Bear Case
The primary concerns are Price/Sales, Price/Book, PEG Ratio. Some valuation metrics including PEG Ratio (2.29), Price/Sales (9.86), Price/Book (6.39) suggest expensive pricing. Growth concerns include Revenue Growth at 9.50%, which may limit upside.
Key Dynamics to Monitor
Three factors to monitor going forward. First, whether Price/Sales improves, as this is the primary drag on the overall score. Second, margin trajectory, with Return on Equity at 22.50% currently healthy but needing to be sustained. Third, growth sustainability, with Revenue Growth at 9.50% needing to reaccelerate.
Risk Considerations
Based on the metric profile, this is a moderate-to-high risk investment. The weight of evidence leans positive, with more strengths than concerns. Investors should size positions according to their risk tolerance and maintain diversification.
Bottom Line
Mixed fundamentals with both positives (Operating Margin, EPS Growth) and negatives (Price/Sales, Price/Book). A cautious approach is warranted. Monitor for improvement in weak areas before increasing conviction.
Disclaimer: Smart Analysis is a scoring system developed by WallStSmart Team. Scores update daily using multi-model valuation framework. Always conduct your own research and consult with financial advisors before making investment decisions.
WallStSmart Analysis Synopsis
Data-driven financial summary for Vertex Pharmaceuticals Inc (VRTX) · HEALTHCARE › BIOTECHNOLOGY
The Big Picture
Vertex Pharmaceuticals Inc is a mature, profitable business with steady cash generation. Revenue reached 12.0B with 10% growth year-over-year. Profit margins are strong at 32.9%, reflecting pricing power and operational efficiency.
Key Findings
ROE of 2250.0% means the company generates strong returns on shareholder equity. Above 20% is considered top-tier.
Profit margin of 32.9% and operating margin of 39.6% demonstrate strong pricing power and operational efficiency.
What to Watch Next
Sector dynamics: monitor BIOTECHNOLOGY industry trends, competitive moves, and regulatory changes that could impact Vertex Pharmaceuticals Inc.
Bottom Line
Vertex Pharmaceuticals Inc is a well-established business delivering consistent profitability with 32.9% margins. The growth phase may be slowing, but strong cash generation and operational efficiency make it suitable for investors seeking reliability over excitement.
This synopsis is generated from publicly available financial data. It is not financial advice. Always conduct your own research and consult a qualified financial advisor before making investment decisions.
Insider Transactions(136 last 3 months)
| Insider | Type | Shares |
|---|---|---|
MCKECHNIE, DUNCAN EVP, Chief Commercial Officer | Sell | -2,633 |
| Insider | Type | Shares |
|---|---|---|
MCKECHNIE, DUNCAN EVP, Chief Commercial Officer | Sell | -2,437 |
| Insider | Type | Shares |
|---|---|---|
LIU, JOY EVP and Chief Legal Officer | Sell | -892 |
| Insider | Type | Shares |
|---|---|---|
AMBROSE, KRISTEN SVP & Chief Accounting Officer | Sell | -357 |
| Insider | Type | Shares |
|---|---|---|
TATSIS, OURANIA EVP, Chief Reg. & Quality Off. | Sell | -4,500 |
Data sourced from SEC Form 4 filings
Last updated: 4:15:34 AM
About Vertex Pharmaceuticals Inc(VRTX)
NASDAQ
HEALTHCARE
BIOTECHNOLOGY
USA
Vertex Pharmaceuticals, Inc. is an American biopharmaceutical company based in Boston, Massachusetts.